This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Drug probes resumed by UK CMA following Covid-19 delay

( July 20, 2020, 10:41 GMT | Official Statement) -- MLex Summary: The UK Competition and Markets Authority has resumed two antitrust probes into the supply of drugs. The first is the CMA's investigation into AMCo (now Advanz Pharma), Morningside Healthcare, Morningside Pharmaceuticals and Alliance Healthcare over the supply of antibiotic Nitrofurantoin. The second is its investigation into Focus Pharmaceuticals, Medreich, Alliance Pharmaceuticals and Lexon over the supply of prochlorperazine, a nausea drug. The CMA said it is considering written and oral representations on the Statement of Objections and will make a final decision on the case outcome by spring 2021. The CMA had previously paused the investigations due to the Covid-19 pandemic.Statements follow....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections